Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Lecanemab-irmb (Leqembi)

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)FDA safety resources (1)

Review note before using historical content

Leqembi historical MRI schedule is superseded

The restored article omits the earlier MRI monitoring subsequently required for ARIA safety. Follow the current label section 2.4, Monitoring for ARIA, and its route-specific timing. The current July 2026 label is newer than the August 2025 FDA communication; the older article and alert are not a complete current schedule.

Safety sources and review scope
  • Leqembi U.S. prescribing information (opens in a new tab)Source URL: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975

    Exact location: 2.4 Monitoring and Dosing Interruption for Amyloid Related Imaging Abnormalities, Monitoring for ARIA; UUID36eb916a-f7a9-4532-8bce-0c1c2be64a98

    Source family: Leqembi U.S. prescribing information

    Scope: SPL version24 effective2026-07-21, printed revision07/2026. Current label expresses monitoring in treatment months and covers IV/SC routes. No route or dose interchangeability inferred.

  • FDA Leqembi postmarketing safety assessment (opens in a new tab)Source URL: https://www.fda.gov/drugs/drug-safety-communications/fda-recommend-additional-earlier-mri-monitoring-patients-alzheimers-disease-taking-leqembi-lecanemab

    Exact location: 2025-08-28 communication: What Safety Concern Is FDA Announcing?; What Is FDA Doing?

    Source family: FDA Leqembi postmarketing safety assessment

    Scope: Documents the earlier MRI safety change in2025. It is not the latest complete2026 route-specific schedule; current SPL controls the displayed link.

Historical source in disagreement: Archived GlobalRPh article (opens in a new tab)Historical source URL: https://globalrph.com/dilution/leqembi-lecanemab-irmb/

Historical location: DOSAGE AND ADMINISTRATION2.3, Monitoring for ARIA

Review-note ID: H62-SAFETY-LEQEMBI-MRI. The historical source remains preserved; this note does not qualify its complete monograph.

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

LEQEMBI® -lecanemab-irmb (opens in a new tab)Original source URL: https://globalrph.com/dilution/leqembi-lecanemab-irmb/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/leqembi-lecanemab-irmb/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:48:02.061609+00:00
Source location
div.post-content
Packaged content SHA-256
b644e7d44756da4b7826bc02fc5eb13d5c5d1ed545410da0f15bcd19e193f48a
Original response SHA-256
bb48a662f4b0e2bd63338426ef9a32323d473d68a5de47029dbd9211d21a1041
Source body SHA-256
2c240a1abeb43cd0543b6b46c0784694dbe0d95847bacc615e9b26171016658d

LEQEMBI® (lecanemab-irmb) injection

PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information (pdf)]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

0.9% Sodium Chloride (NS)

Standard Dilutions [Amt of drug] [Infusion vol] [Infusion rate] Return to article top

[ 10 mg/kg ] [250 mL ] [60 minutes]
Vial: 100 mg/mL
Must use a terminal low-protein binding 0.2 micron in-line filter
The recommended dosage of LEQEMBI is 10 mg/kg that must be diluted then administered as an intravenous infusion over approximately one hour, once every two weeks.

If an infusion is missed, administer the next dose as soon as possible.

  • Prior to administration, LEQEMBI must be diluted in 250 mL of 0.9% Sodium Chloride Injection, USP.Use aseptic technique when preparing the LEQEMBI diluted solution for intravenous infusion.Calculate the dose (mg), the total volume (mL) of LEQEMBI solution required, and the number of vials needed based on the patient's actual body weight and the recommended dose of 10 mg/kg. Each vial contains a LEQEMBI concentration of 100 mg/mL.
  • Each vial is for one-time use only. Discard any unused portion.
  • Gently invert the infusion bag containing the LEQEMBI diluted solution to mix completely. Do not shake.
  • After dilution, immediate use is recommended [see DESCRIPTION (11)]. If not administered immediately, store LEQEMBI refrigerated at 2°C to 8°C (36°F to 46°F) for up to 4 hours, or at room temperature up to 30°C (86°F) for up to 4 hours. Do not freeze.
  • Infuse the entire volume of the LEQEMBI diluted solution intravenously over approximately one hour through an intravenous line containing a terminal low-protein binding 0.2 micron in-line filter. Flush infusion line to ensure all LEQEMBI is administered.

See warnings and precautions below.
WARNING:
WARNING: AMYLOID RELATED IMAGING ABNORMALITIES
Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur. Serious intracerebral hemorrhages, some of which have been fatal, have been observed in patients treated with this class of medications [see WARNINGS AND PRECAUTIONS (5.1), ADVERSE REACTIONS (6.1)].

ApoE ε4 Homozygotes

Patients who are apolipoprotein E ε4 (ApoE ε4) homozygotes (approximately 15% of Alzheimer's disease patients) treated with this class of medications, including LEQEMBI, have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed they can still be treated with LEQEMBI; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA [see WARNINGS AND PRECAUTIONS (5.1)].

Consider the benefit of LEQEMBI for the treatment of Alzheimer's disease and potential risk of serious adverse events associated with ARIA when deciding to initiate treatment with LEQEMBI [see WARNINGS AND PRECAUTIONS (5.1) and CLINICAL STUDIES (14)].Drug information (pdf)

Description:
Lecanemab-irmb is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta, and is expressed in a Chinese hamster ovary cell line. Lecanemab-irmb has an approximate molecular weight of 150 kDa.

LEQEMBI (lecanemab-irmb) injection is a preservative-free, sterile, clear to opalescent and colorless to pale yellow solution for intravenous use by infusion after dilution. LEQEMBI is supplied in single-dose vials available in concentrations of 500 mg/5 mL (100 mg/mL) or 200 mg/2 mL (100 mg/mL).

Each mL of solution contains 100 mg of lecanemab-irmb and arginine hydrochloride (42.13 mg), histidine (0.18 mg), histidine hydrochloride monohydrate (4.99 mg), polysorbate 80 (0.50 mg), and Water for Injection at an approximate pH of 5.0.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:

Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease. LEQEMBI reduces amyloid beta plaques, as evaluated in Study 1 and Study 2.

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:
LEQEMBI is indicated for the treatment of Alzheimer's disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

CONTRAINDICATIONS Return to article top

Contraindications:

LEQEMBI is contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients of LEQEMBI.

PRECAUTIONS Return to article top

Leqembi historical MRI schedule is superseded

The restored article omits the earlier MRI monitoring subsequently required for ARIA safety. Follow the current label section 2.4, Monitoring for ARIA, and its route-specific timing. The current July 2026 label is newer than the August 2025 FDA communication; the older article and alert are not a complete current schedule.

Current-source reference: 2.4 Monitoring and Dosing Interruption for Amyloid Related Imaging Abnormalities, Monitoring for ARIA; UUID36eb916a-f7a9-4532-8bce-0c1c2be64a98

Current-source reference: 2025-08-28 communication: What Safety Concern Is FDA Announcing?; What Is FDA Doing?

WARNINGS AND PRECAUTIONS:
  • Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment with LEQEMBI. Risk of ARIA, including symptomatic ARIA, was increased in apolipoprotein E ε4 homozygotes compared to heterozygotes and noncarriers. If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including MRI scanning if indicated. (2.3, 5.1) Drug information (pdf)
  • Infusion-Related Reactions: The infusion rate may be reduced, or the infusion may be discontinued, and appropriate therapy administered as clinically indicated. Consider pre-medication at subsequent dosing with antihistamines, non-steroidal anti-inflammatory drugs, or corticosteroids. (5.3)

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:
Most common adverse reactions (at approximately 10% and higher incidence compared to placebo): infusion-related reactions, amyloid related imaging abnormality-microhemorrhages, amyloid related imaging abnormality-edema/effusion, and headache. (6.1)

See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide. Drug information (pdf)

DOSAGE AND ADMINISTRATION Return to article top

Leqembi historical MRI schedule is superseded

The restored article omits the earlier MRI monitoring subsequently required for ARIA safety. Follow the current label section 2.4, Monitoring for ARIA, and its route-specific timing. The current July 2026 label is newer than the August 2025 FDA communication; the older article and alert are not a complete current schedule.

Current-source reference: 2.4 Monitoring and Dosing Interruption for Amyloid Related Imaging Abnormalities, Monitoring for ARIA; UUID36eb916a-f7a9-4532-8bce-0c1c2be64a98

Current-source reference: 2025-08-28 communication: What Safety Concern Is FDA Announcing?; What Is FDA Doing?

DOSAGE AND ADMINISTRATION:

2.1 Patient Selection
Confirm the presence of amyloid beta pathology prior to initiating treatment [see CLINICAL PHARMACOLOGY (12.1)]. Drug information (pdf)

2.2 Dosing Instructions
The recommended dosage of LEQEMBI is 10 mg/kg that must be diluted then administered as an intravenous infusion over approximately one hour, once every two weeks.

If an infusion is missed, administer the next dose as soon as possible.

2.3 Monitoring and Dosing Interruption for Amyloid Related Imaging Abnormalities
LEQEMBI can cause amyloid related imaging abnormalities -edema (ARIA-E) and -hemosiderin deposition (ARIA-H) [see WARNINGS AND PRECAUTIONS (5.1)].

Monitoring for ARIA

Obtain a recent baseline brain magnetic resonance imaging (MRI) prior to initiating treatment with LEQEMBI. Obtain an MRI prior to the 5th, 7th, and 14th infusions. If a patient experiences symptoms suggestive of ARIA, clinical evaluation should be performed, including an MRI if indicated.

Recommendations for Dosing Interruptions in Patients with ARIA

ARIA-E

The recommendations for dosing interruptions for patients with ARIA-E are provided in Table 1.

Table 1: Dosing Recommendations for Patients with ARIA-E
Clinical Symptom Severity1 ARIA-E Severity on MRI2
Mild Moderate Severe
Asymptomatic May continue dosing Suspend dosing3 Suspend dosing3
Mild May continue dosing based on clinical judgment Suspend dosing3
Moderate or Severe Suspend dosing3

1 Clinical Symptom Severity Categories:
Mild: discomfort noticed, but no disruption of normal daily activity.
Moderate: discomfort sufficient to reduce or affect normal daily activity.
Severe: incapacitating, with inability to work or to perform normal daily activity.

2 See TABLE 3 for MRI severity [WARNINGS AND PRECAUTIONS (5.1)].
Drug information (pdf)

3 Suspend until MRI demonstrates radiographic resolution and symptoms, if present, resolve; consider a follow-up MRI to assess for resolution 2 to 4 months after initial identification. Resumption of dosing should be guided by clinical judgment.

ARIA-H

The recommendations for dosing interruptions for patients with ARIA-H are provided in Table 2.

Table 2: Dosing Recommendations for Patients with ARIA-H
Clinical Symptom Severity ARIA-H Severity on MRI1
Mild Moderate Severe
Asymptomatic May continue dosing Suspend dosing2 Suspend dosing3
Symptomatic Suspend dosing2 Suspend dosing2

1 See TABLE 3 for MRI severity [Warnings and Precautions (5.1)].
Drug information (pdf)

2 Suspend until MRI demonstrates radiographic stabilization and symptoms, if present, resolve; resumption of dosing should be guided by clinical judgment; consider a follow-up MRI to assess for stabilization 2 to 4 months after initial identification.

3 Suspend until MRI demonstrates radiographic stabilization and symptoms, if present, resolve; use clinical judgment in considering whether to continue treatment or permanently discontinue LEQEMBI.

In patients who develop intracerebral hemorrhage greater than 1 cm in diameter during treatment with LEQEMBI, suspend dosing until MRI demonstrates radiographic stabilization and symptoms, if present, resolve. Use clinical judgment in considering whether to continue treatment after radiographic stabilization and resolution of symptoms or permanently discontinue LEQEMBI.

2.4 Dilution Instructions
  • Prior to administration, LEQEMBI must be diluted in 250 mL of 0.9% Sodium Chloride Injection, USP.
  • Use aseptic technique when preparing the LEQEMBI diluted solution for intravenous infusion.
  • Calculate the dose (mg), the total volume (mL) of LEQEMBI solution required, and the number of vials needed based on the patient's actual body weight and the recommended dose of 10 mg/kg. Each vial contains a LEQEMBI concentration of 100 mg/mL.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Check that the LEQEMBI solution is clear to opalescent and colorless to pale yellow. Do not use if opaque particles, discoloration, or other foreign particles are present.
  • Remove the flip-off cap from the vial. Insert the sterile syringe needle into the vial through the center of the rubber stopper.
  • Withdraw the required volume of LEQEMBI from the vial(s) and add to an infusion bag containing 250 mL of 0.9% Sodium Chloride Injection, USP.
  • Each vial is for one-time use only. Discard any unused portion.
  • Gently invert the infusion bag containing the LEQEMBI diluted solution to mix completely. Do not shake.
  • After dilution, immediate use is recommended [see DESCRIPTION (11)]. If not administered immediately, store LEQEMBI refrigerated at 2°C to 8°C (36°F to 46°F) for up to 4 hours, or at room temperature up to 30°C (86°F) for up to 4 hours. Do not freeze.

2.5 Administration Instructions

  • Visually inspect the LEQEMBI diluted solution for particles or discoloration prior to administration. Do not use if it is discolored, or opaque or foreign particles are seen.
  • Prior to infusion, allow the LEQEMBI diluted solution to warm to room temperature.
  • Infuse the entire volume of the LEQEMBI diluted solution intravenously over approximately one hour through an intravenous line containing a terminal low-protein binding 0.2 micron in-line filter. Flush infusion line to ensure all LEQEMBI is administered.
  • Monitor for any signs or symptoms of an infusion-related reaction. The infusion rate may be reduced, or the infusion may be discontinued, and appropriate therapy administered as clinically indicated. Consider pre-medication at subsequent dosing with antihistamines, non-steroidal anti-inflammatory drugs, or corticosteroids [see WARNINGS AND PRECAUTIONS (5.3)].
DOSAGE FORMS AND STRENGTHS:

Injection:

  • 500 mg/5 mL (100 mg/mL) solution in a single-dose vial
  • 200 mg/2 mL (100 mg/mL) solution in a single-dose vial

Storage and Stability Return to article top

Storage and Handling
Unopened Vial
Store in a refrigerator at 2°C to 8°C (36°F to 46°F).
Store in the original carton to protect from light.
Do not freeze or shake.

Diluted Solution
After dilution, immediate use is recommended [see DESCRIPTION (11)]. If not administered immediately, store LEQEMBI refrigerated at 2°C to 8°C (36°F to 46°F) for up to 4 hours, or at room temperature up to 30°C (86°F) for up to 4 hours. Do not freeze.

Open this historical article on its own

FDA safety resources for this medication (1)

Read the linked communication and current prescribing information before use. Resource dates and affected product scopes differ; a listed resource is not a full monograph or a lot-specific clearance.

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      lecanemab-irmb-leqembi
      Source IDH51-24AA87D1674EC032804E17C8
      Generic name
      Lecanemab-irmb (Leqembi)
      Source IDH51-0A8CD42DC6328EE852FDAF38
      Class
      Biologics and immunotherapy
      Source IDH51-FD8ABF348F343645278D5934
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-BF021E219D666B99DBEB6690
      Primary uses
      1. The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic.
        Source IDH51-741333407A775A5531F76B49
      Mechanism
      Preferentially binds soluble aggregated amyloid-beta protofibrils and promotes clearance.
      Source IDH51-7627F4268814CD4372349529
      Mechanism level
      drug_specific
      Source IDH51-043C13053E8DF66AF6DB8B74
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-8FDC08F2D4EC820FEDEDE3CC
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-E7B58E310D692A951527E71E
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-7DC5707A5EC0112A3FC03E86
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-D33A961FDBA0F4A95E1C8FEA
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-80296A1CA0A7F80D1754D98C
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-5DEEA760FE93215D3050D76E
      Legacy title
      Lecanemab-irmb (Leqembi)
      Source IDH51-2B03ACA422950E358626B86C
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-57305C030BE390D3753567E1
      Search text
      Lecanemab-irmb (Leqembi) Biologics and immunotherapy Legacy GlobalRPh directory entry The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic. Preferentially binds soluble aggregated amyloid-beta protofibrils and promotes clearance. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-2888F81A929E774CE1743A15
      Official access mode
      none
      Source IDH51-A7494E1E475B68BDC158C1B6
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-FBF0EB5A53EA251D72FBC49F

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-5502985D06640B26336D5046
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-3B03ECE08F27CE8B86690205
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-5CE21A4EA659B2496CE6A381

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-0DDB20E3C3E56701F1C6E124

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-687508F229E249C6B980D5BF
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      lecanemab-irmb-leqembi
      Source IDH51-2C2952163E7BF3A8C15A7F60
      Legacy title
      Lecanemab-irmb (Leqembi)
      Source IDH51-9D586D84DD8BD2B066A12B5A
      Generic name
      Lecanemab-irmb (Leqembi)
      Source IDH51-0B09217A9A1E913D066EA023
      Class
      Biologics and immunotherapy
      Source IDH51-C3140A8A01B0185E276C6848
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-CA03162ABAAE260A870DB694
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-19CC121B52DA403CDEA0D222
      Populations
      1. Population not yet normalized
        Source IDH51-D1CEE50E88CEA9B7F78EACD1
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-79C98BC36E5AE8D98234F969
      High alert
      false
      Source IDH51-EB82ABD2FBEAC5870F495A0D
      Hazardous
      false
      Source IDH51-DB0282252A72C4F86ECAC0E6
      Status
      Legacy migration
      Source IDH51-48E1E7135A3A8373B360058F
      Version added
      Legacy
      Source IDH51-93701187A5AE32CA3E926149
      Sources
      LabelUrlKind
      Source IDH51-34AF5FA3BFCEFA565C800790
      GlobalRPh legacy IV dilution monograph
      Source IDH51-AB893C4002AA710A9BE5ABFA
      		legacy:auto
      Source IDH51-6F6D0348E79E9287F35591D5
      		Legacy
      Source IDH51-7669F76B81F1CE770194801B
      Clinical release verification
      Audit version
      3.4
      Source IDH51-FA93871626874491C89C9D75
      Audited on
      2026-08-30
      Source IDH51-F27FE9AFFE47BA4A3E20838C
      Level
      red
      Source IDH51-DD7BC708F924C2F8E5A5D0E1
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-86E62177B8AA7A59D8285B31
      Exact current label candidate
      false
      Source IDH51-8EC7187B72E58BCCF7E9EAFD
      Reference url count
      0
      Source IDH51-4A1B73FEECD37971BFB14AF4
      Broken reference count
      0
      Source IDH51-FD6D969DE16A19FC77B0374B
      Point of use confirmation required
      true
      Source IDH51-68E3ED810BBABA1CA8E5175A
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-160194C871AD13CD7FCED08A

      Dosing source fields

      Id
      lecanemab-irmb-leqembi
      Source IDH51-2A73248D56129E6B11F1CC10
      Generic name
      Lecanemab-irmb (Leqembi)
      Source IDH51-F412DB21D6804CE6471BE30C
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-A021512110A3FE5073146661
      Package insert
      Query name
      Lecanemab-irmb
      Source IDH51-96897D4C9E3B0BAD51A6770F
      Product and route must match
      true
      Source IDH51-CC5814DABC5C774FB8E67735
      Live current label enabled
      false
      Source IDH51-940C209D8D58FE9559164E8E
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-4C444677288C193925F1069B
      Direct official label access enabled
      true
      Source IDH51-79178BFC287895547F4A52E0
      Outbound server request required
      false
      Source IDH51-7B4B205A4733C8D4DBB2D7BF
      Local summary status
      not_bundled
      Source IDH51-39321A74ECD454B87F823EA4
      Clinical review
      Locally normalized
      false
      Source IDH51-44AEFD8AA477FEB7631CD3E2
      Reviewed
      2026-08-29
      Source IDH51-548772F95147CFAA7D42845E
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-A1A7A6A691C18F6DF9299208
      Clinical release verification
      Audit version
      3.4
      Source IDH51-D925945C3339F30B5BF21777
      Audited on
      2026-08-30
      Source IDH51-DEFB086770B68BC26F33991F
      Level
      red
      Source IDH51-746F8AD61020286394FEA80F
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-E79E91E998F1ADB080A47A4B
      Exact current label candidate
      false
      Source IDH51-608429F78143C13E1B7093AB
      Reference url count
      0
      Source IDH51-E5151F2569D56DC8049742C8
      Broken reference count
      0
      Source IDH51-F61DDD6EB37F80EF97A45BDE
      Point of use confirmation required
      true
      Source IDH51-75F663068F1B5C9836950A8B
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-1515D9811B928F8E4CBF5A97
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      lecanemab-irmb-leqembi
      Source IDH51-6F2C8B470DDA4211E156BF49
      Name
      Lecanemab-irmb (Leqembi)
      Source IDH51-84C6CDFE36F057F091E69855
      Therapeutic class
      Biologics and immunotherapy
      Source IDH51-05E86E1AB8BD09726D8AF751
      Review version
      3.1
      Source IDH51-44DDA902E0F6FAD2582A98AA
      Review date
      2026-08-30
      Source IDH51-629B1D96D932464FFCBB06A1
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-7E3CA5FDF2E98F7DB8149C15
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-21993D0F2F05124FD96E119B
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-49FFCA21A0C1F3841FADCA08
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-1A49DFDBC622ADD3E059F520
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-99E98B96B5E038B51D11BA24
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-433D053171677C7295D5700E
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-424BBF6347F2F769CCC68093
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-8DF2443CD790558B310E3279
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-645C1EEEF0AD875AE3A469E6
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-0DFE2D63D37D647B1DB0A0FC
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-3B449A7B8F9A06F4AD9A4EE0
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-A0902A4F823E665A36357222
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-E661BBBAC5E84A3D058268EE
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-5DD80407B4EE631A0E67DDF4
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-A37184104449277CD6C53922
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-A83DD9EFCEB8A75C2D8F87D4
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-EE8D8800679F4A3FC796F8F4
      Adult dosing range
      Primary
      not_found
      Source IDH51-D62367314900200E0E0CB271
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-8A41EFEEE99708F2836E568E
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-64B7D7716BD8CB0FE4BBA1DA
      Infusion time
      Primary
      not_found
      Source IDH51-AAF980943BA419BD5C681456
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-FDEDB0857FE03342894AFFE3
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-ABE5EA999328A2ABE3C85C05
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-5BEEE9598C550672C123F639
      Guide generation allowed
      false
      Source IDH51-1B9D999AF650C53968AF9380
      Pediatric
      Applicability
      not_established
      Source IDH51-EF8021DE8401BA25C45387D0
      Guide generation allowed
      false
      Source IDH51-D100A2AA503B6D48935CDFBC
      Neonatal
      Applicability
      not_established
      Source IDH51-DBAFE96ECAE9B18181E6CD89
      Guide generation allowed
      false
      Source IDH51-C1F026126E3B607860A8B16C
      Route presence
      Structured dilution
      false
      Source IDH51-ED8409836A03241A9E5D7D94
      Iv push
      false
      Source IDH51-0AF568235E01ECE60217F346
      Continuous infusion
      false
      Source IDH51-DC2E4E394736287007D2EB1A
      Pediatric source
      false
      Source IDH51-8586CDDAF63D399751705F5C
      Neonatal source
      false
      Source IDH51-ADEC4AAB481942538C4C710C
      Legacy reference
      Status
      not_available
      Source IDH51-B9D594A53F4BCBD4404651E7
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-491D0E098565257E2CE5B1EC
      Source files
      1. catalog.json
        Source IDH51-D550B36732D957823C5E8C7F
      2. dosing.json
        Source IDH51-479B02FCAD0E41A7F96683C9
      3. legacy-map.json
        Source IDH51-42D8A6DC4BC47ACEB4493677
      4. review-queue.json
        Source IDH51-005B8DF0D8A0A16CD21A82F8
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-7971093ABD2E5938E2348E14
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-2C2952163E7BF3A8C15A7F60catalog.json
      /records/146/id      		Historical; current review incomplete
      H51-9D586D84DD8BD2B066A12B5Acatalog.json
      /records/146/legacy_title      		Historical; current review incomplete
      H51-0B09217A9A1E913D066EA023catalog.json
      /records/146/generic_name      		Historical; current review incomplete
      H51-C3140A8A01B0185E276C6848catalog.json
      /records/146/class      		Historical; current review incomplete
      H51-CA03162ABAAE260A870DB694catalog.json
      /records/146/subclass      		Historical; current review incomplete
      H51-19CC121B52DA403CDEA0D222catalog.json
      /records/146/summary      		Historical; current review incomplete
      H51-0DDB20E3C3E56701F1C6E124catalog.json
      /records/146/warnings/0      		Historical; current review incomplete
      H51-687508F229E249C6B980D5BFcatalog.json
      /records/146/stability_notes/0      		Historical; current review incomplete
      H51-D1CEE50E88CEA9B7F78EACD1catalog.json
      /records/146/populations/0      		Historical; current review incomplete
      H51-79C98BC36E5AE8D98234F969catalog.json
      /records/146/evidence_tier      		Historical; current review incomplete
      H51-EB82ABD2FBEAC5870F495A0Dcatalog.json
      /records/146/high_alert      		Historical; current review incomplete
      H51-DB0282252A72C4F86ECAC0E6catalog.json
      /records/146/hazardous      		Historical; current review incomplete
      H51-48E1E7135A3A8373B360058Fcatalog.json
      /records/146/status      		Historical; current review incomplete
      H51-414FB914FF622CE213ECDA9Ccatalog.json
      /records/146/reviewed      		Historical; current review incomplete
      H51-93701187A5AE32CA3E926149catalog.json
      /records/146/version_added      		Historical; current review incomplete
      H51-34AF5FA3BFCEFA565C800790catalog.json
      /records/146/sources/0      		Historical; current review incomplete
      H51-AB893C4002AA710A9BE5ABFAcatalog.json
      /records/146/sources/0/label      		Historical; current review incomplete
      H51-6F6D0348E79E9287F35591D5catalog.json
      /records/146/sources/0/url      		Historical; current review incomplete
      H51-7669F76B81F1CE770194801Bcatalog.json
      /records/146/sources/0/kind      		Historical; current review incomplete
      H51-FA93871626874491C89C9D75catalog.json
      /records/146/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-F27FE9AFFE47BA4A3E20838Ccatalog.json
      /records/146/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-DD7BC708F924C2F8E5A5D0E1catalog.json
      /records/146/clinical_release_verification/level      		Historical; current review incomplete
      H51-86E62177B8AA7A59D8285B31catalog.json
      /records/146/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-8EC7187B72E58BCCF7E9EAFDcatalog.json
      /records/146/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-074DEBD408C3FF54C971DE80catalog.json
      /records/146/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-F5BE0654B0E19C32A0701A28catalog.json
      /records/146/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-AF7C1F8A7BFF91BA8F4839EAcatalog.json
      /records/146/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-4A1B73FEECD37971BFB14AF4catalog.json
      /records/146/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-FD6D969DE16A19FC77B0374Bcatalog.json
      /records/146/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-68E3ED810BBABA1CA8E5175Acatalog.json
      /records/146/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-160194C871AD13CD7FCED08Acatalog.json
      /records/146/clinical_release_verification/note      		Historical; current review incomplete
      H51-056A9272D989D3E058C18544catalog.json
      /records/146/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-2A73248D56129E6B11F1CC10dosing.json
      /records/146/id      		Historical; current review incomplete
      H51-F412DB21D6804CE6471BE30Cdosing.json
      /records/146/generic_name      		Historical; current review incomplete
      H51-A021512110A3FE5073146661dosing.json
      /records/146/coverage_status      		Historical; current review incomplete
      H51-96897D4C9E3B0BAD51A6770Fdosing.json
      /records/146/package_insert/query_name      		Historical; current review incomplete
      H51-5D800D71AAE6F4AA7BB8C61Edosing.json
      /records/146/package_insert/preferred_setid      		Historical; current review incomplete
      H51-CC5814DABC5C774FB8E67735dosing.json
      /records/146/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-940C209D8D58FE9559164E8Edosing.json
      /records/146/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-4C444677288C193925F1069Bdosing.json
      /records/146/package_insert/source_priority      		Historical; current review incomplete
      H51-79178BFC287895547F4A52E0dosing.json
      /records/146/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-7B4B205A4733C8D4DBB2D7BFdosing.json
      /records/146/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-39321A74ECD454B87F823EA4dosing.json
      /records/146/package_insert/local_summary_status      		Historical; current review incomplete
      H51-5502985D06640B26336D5046dosing.json
      /records/146/renal/classification      		Historical; current review incomplete
      H51-3B03ECE08F27CE8B86690205dosing.json
      /records/146/renal/summary      		Historical; current review incomplete
      H51-5CE21A4EA659B2496CE6A381dosing.json
      /records/146/renal/method_note      		Historical; current review incomplete
      H51-44AEFD8AA477FEB7631CD3E2dosing.json
      /records/146/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-548772F95147CFAA7D42845Edosing.json
      /records/146/clinical_review/reviewed      		Historical; current review incomplete
      H51-A1A7A6A691C18F6DF9299208dosing.json
      /records/146/clinical_review/status      		Historical; current review incomplete
      H51-D925945C3339F30B5BF21777dosing.json
      /records/146/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-DEFB086770B68BC26F33991Fdosing.json
      /records/146/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-746F8AD61020286394FEA80Fdosing.json
      /records/146/clinical_release_verification/level      		Historical; current review incomplete
      H51-E79E91E998F1ADB080A47A4Bdosing.json
      /records/146/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-608429F78143C13E1B7093ABdosing.json
      /records/146/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-EC20B4B0168612AC71981A01dosing.json
      /records/146/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-64C481F8D9E7D6C2EB7FE0E6dosing.json
      /records/146/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-0867741C1BEFAD21AAACCED7dosing.json
      /records/146/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-E5151F2569D56DC8049742C8dosing.json
      /records/146/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-F61DDD6EB37F80EF97A45BDEdosing.json
      /records/146/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-75F663068F1B5C9836950A8Bdosing.json
      /records/146/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-1515D9811B928F8E4CBF5A97dosing.json
      /records/146/clinical_release_verification/note      		Historical; current review incomplete
      H51-892895D813F067FB8F28D096dosing.json
      /records/146/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-24AA87D1674EC032804E17C8first-look-v5.1.json
      /records/146/id      		Historical; current review incomplete
      H51-0A8CD42DC6328EE852FDAF38first-look-v5.1.json
      /records/146/generic_name      		Historical; current review incomplete
      H51-FD8ABF348F343645278D5934first-look-v5.1.json
      /records/146/class      		Historical; current review incomplete
      H51-BF021E219D666B99DBEB6690first-look-v5.1.json
      /records/146/subclass      		Historical; current review incomplete
      H51-741333407A775A5531F76B49first-look-v5.1.json
      /records/146/primary_uses/0      		Historical; current review incomplete
      H51-7627F4268814CD4372349529first-look-v5.1.json
      /records/146/mechanism      		Historical; current review incomplete
      H51-043C13053E8DF66AF6DB8B74first-look-v5.1.json
      /records/146/mechanism_level      		Historical; current review incomplete
      H51-8FDC08F2D4EC820FEDEDE3CCfirst-look-v5.1.json
      /records/146/basic_dosing_orientation      		Historical; current review incomplete
      H51-E7B58E310D692A951527E71Efirst-look-v5.1.json
      /records/146/administration_orientation      		Historical; current review incomplete
      H51-7DC5707A5EC0112A3FC03E86first-look-v5.1.json
      /records/146/renal_and_population_orientation      		Historical; current review incomplete
      H51-D33A961FDBA0F4A95E1C8FEAfirst-look-v5.1.json
      /records/146/key_safety_orientation/0      		Historical; current review incomplete
      H51-80296A1CA0A7F80D1754D98Cfirst-look-v5.1.json
      /records/146/coverage_path      		Historical; current review incomplete
      H51-5DEEA760FE93215D3050D76Efirst-look-v5.1.json
      /records/146/coverage_path_label      		Historical; current review incomplete
      H51-98C47D8433A37C768BB70C14first-look-v5.1.json
      /records/146/official_label_url      		Historical; current review incomplete
      H51-2B03ACA422950E358626B86Cfirst-look-v5.1.json
      /records/146/legacy_title      		Historical; current review incomplete
      H51-57305C030BE390D3753567E1first-look-v5.1.json
      /records/146/review_note      		Historical; current review incomplete
      H51-2888F81A929E774CE1743A15first-look-v5.1.json
      /records/146/search_text      		Historical; current review incomplete
      H51-0AF3554F033356BBCF60445Afirst-look-v5.1.json
      /records/146/official_search_url      		Historical; current review incomplete
      H51-A7494E1E475B68BDC158C1B6first-look-v5.1.json
      /records/146/official_access_mode      		Historical; current review incomplete
      H51-0EB3349B7AC52B0501AA679Ffirst-look-v5.1.json
      /records/146/official_access_url      		Historical; current review incomplete
      H51-0B63FB8FEF09FCCD83684797first-look-v5.1.json
      /records/146/official_search_query      		Historical; current review incomplete
      H51-FBF0EB5A53EA251D72FBC49Ffirst-look-v5.1.json
      /records/146/official_access_reason      		Historical; current review incomplete
      H51-6F2C8B470DDA4211E156BF49preparation-assessments-v3.8.json
      /146/id      		Historical; current review incomplete
      H51-84C6CDFE36F057F091E69855preparation-assessments-v3.8.json
      /146/name      		Historical; current review incomplete
      H51-BFC7A98CD63C71A5BC5E2B53preparation-assessments-v3.8.json
      /146/brands      		Historical; current review incomplete
      H51-05E86E1AB8BD09726D8AF751preparation-assessments-v3.8.json
      /146/therapeutic_class      		Historical; current review incomplete
      H51-44DDA902E0F6FAD2582A98AApreparation-assessments-v3.8.json
      /146/review_version      		Historical; current review incomplete
      H51-629B1D96D932464FFCBB06A1preparation-assessments-v3.8.json
      /146/review_date      		Historical; current review incomplete
      H51-7E3CA5FDF2E98F7DB8149C15preparation-assessments-v3.8.json
      /146/release_status      		Historical; current review incomplete
      H51-21993D0F2F05124FD96E119Bpreparation-assessments-v3.8.json
      /146/market_status/status      		Historical; current review incomplete
      H51-49FFCA21A0C1F3841FADCA08preparation-assessments-v3.8.json
      /146/market_status/basis      		Historical; current review incomplete
      H51-1A49DFDBC622ADD3E059F520preparation-assessments-v3.8.json
      /146/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-99E98B96B5E038B51D11BA24preparation-assessments-v3.8.json
      /146/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-433D053171677C7295D5700Epreparation-assessments-v3.8.json
      /146/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-424BBF6347F2F769CCC68093preparation-assessments-v3.8.json
      /146/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-8DF2443CD790558B310E3279preparation-assessments-v3.8.json
      /146/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-645C1EEEF0AD875AE3A469E6preparation-assessments-v3.8.json
      /146/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-0DFE2D63D37D647B1DB0A0FCpreparation-assessments-v3.8.json
      /146/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-3B449A7B8F9A06F4AD9A4EE0preparation-assessments-v3.8.json
      /146/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-A0902A4F823E665A36357222preparation-assessments-v3.8.json
      /146/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-E21FC0A5AE3F1ADF3810B885preparation-assessments-v3.8.json
      /146/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-089C1CCD97ACF56B881519D6preparation-assessments-v3.8.json
      /146/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-58C7BAF6A336A23273AFF96Epreparation-assessments-v3.8.json
      /146/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-1AE57E85DF57EEC892095439preparation-assessments-v3.8.json
      /146/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-E661BBBAC5E84A3D058268EEpreparation-assessments-v3.8.json
      /146/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-C93F8A67B1E8A5F5D3E04DAApreparation-assessments-v3.8.json
      /146/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-5DD80407B4EE631A0E67DDF4preparation-assessments-v3.8.json
      /146/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-A37184104449277CD6C53922preparation-assessments-v3.8.json
      /146/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-A83DD9EFCEB8A75C2D8F87D4preparation-assessments-v3.8.json
      /146/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-EE8D8800679F4A3FC796F8F4preparation-assessments-v3.8.json
      /146/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-D62367314900200E0E0CB271preparation-assessments-v3.8.json
      /146/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-8A41EFEEE99708F2836E568Epreparation-assessments-v3.8.json
      /146/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-64B7D7716BD8CB0FE4BBA1DApreparation-assessments-v3.8.json
      /146/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-AAF980943BA419BD5C681456preparation-assessments-v3.8.json
      /146/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-FDEDB0857FE03342894AFFE3preparation-assessments-v3.8.json
      /146/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-ABE5EA999328A2ABE3C85C05preparation-assessments-v3.8.json
      /146/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-5BEEE9598C550672C123F639preparation-assessments-v3.8.json
      /146/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-1B9D999AF650C53968AF9380preparation-assessments-v3.8.json
      /146/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-EF8021DE8401BA25C45387D0preparation-assessments-v3.8.json
      /146/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-D100A2AA503B6D48935CDFBCpreparation-assessments-v3.8.json
      /146/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-DBAFE96ECAE9B18181E6CD89preparation-assessments-v3.8.json
      /146/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-C1F026126E3B607860A8B16Cpreparation-assessments-v3.8.json
      /146/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-ED8409836A03241A9E5D7D94preparation-assessments-v3.8.json
      /146/route_presence/structured_dilution      		Historical; current review incomplete
      H51-0AF568235E01ECE60217F346preparation-assessments-v3.8.json
      /146/route_presence/iv_push      		Historical; current review incomplete
      H51-DC2E4E394736287007D2EB1Apreparation-assessments-v3.8.json
      /146/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-8586CDDAF63D399751705F5Cpreparation-assessments-v3.8.json
      /146/route_presence/pediatric_source      		Historical; current review incomplete
      H51-ADEC4AAB481942538C4C710Cpreparation-assessments-v3.8.json
      /146/route_presence/neonatal_source      		Historical; current review incomplete
      H51-B9D594A53F4BCBD4404651E7preparation-assessments-v3.8.json
      /146/legacy_reference/status      		Historical; current review incomplete
      H51-491D0E098565257E2CE5B1ECpreparation-assessments-v3.8.json
      /146/label_resolution/status      		Historical; current review incomplete
      H51-D550B36732D957823C5E8C7Fpreparation-assessments-v3.8.json
      /146/source_files/0      		Historical; current review incomplete
      H51-479B02FCAD0E41A7F96683C9preparation-assessments-v3.8.json
      /146/source_files/1      		Historical; current review incomplete
      H51-42D8A6DC4BC47ACEB4493677preparation-assessments-v3.8.json
      /146/source_files/2      		Historical; current review incomplete
      H51-005B8DF0D8A0A16CD21A82F8preparation-assessments-v3.8.json
      /146/source_files/3      		Historical; current review incomplete
      H51-7971093ABD2E5938E2348E14preparation-assessments-v3.8.json
      /146/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top